Entity
Grail
Grail is a biotechnology company that develops the Galleri multi-cancer early detection blood test, which screens for multiple cancers from a single blood draw. It is an Illumina spinout focused on genomic-based cancer screening.
Why it’s in the news: An FDA advisory panel endorsed Grail's Galleri test, concluding its benefits outweigh the risks, putting the company's regulatory path in the spotlight.
Latest on Grail
- Owning a Home Is Seen as a Financial Holy Grail. But What If It Isn’t?
- STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks
- STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
- On this day in space! Sept. 10, 2011: NASA launches GRAIL probes to the moon to map lumpy lunar gravity
- STAT+: FDA panel to weigh Grail’s Galleri test
- DataGrail report finds your vendor may be sending data to AI models you never approved
- 13F: Arbiter Partners Capital Management Llc holds Grail ($71M)
Connections
7 entities linked to Grail across the news graph.
Also connected to (7)
Arbiter Partners Capital Management LlcOwning a Home Is Seen as a Financial Holy Grail. But What If It Isn’t?STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risksSTAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulatorsGalleriSTATFDA